Skip to main content

Table 2 Qualitative analysis of the projects

From: How to promote adverse drug reaction reports using information systems – a systematic review and meta-analysis

Variable Time period Total (%) Project numbers
<2004 (4 projects) 2005–2007 (4 projects) 2008–2010 (8 projects) 2011–2013 (13 projects)
Geographic area covered by the project       
 Regional 4 3 5 6 18 (62) 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 20, 21, 22, 26, 27, 28, 29
 National 0 1 3 6 10 (34) 1, 3, 6, 9, 15, 18, 19, 23, 24, 25
 International 0 0 0 1 1 (3) 12
Area covered by the project       
 Hospital 4 2 5 4 15 (52) 2, 4, 5, 8, 11, 13, 17, 18, 20, 21, 22, 26, 27, 28, 29
 Community 0 0 0 6 6 (21) 1, 3, 12, 14, 15, 16
 Primary care 0 2 1 1 4 (14) 6, 7, 9, 10
 Other healthcare institutions (different from hospitals or primary care) 0 0 1 2 3 (10) 19, 24, 25
 Clinical trials 0 0 1 0 1 (3) 23
Type of action promoted by the project       
 Passive promotion of ADR reporting 3 3 6 10 22 (76) 4, 5, 6, 8, 9, 10, 11, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29
 Active promotion of ADR reporting 1 1 2 3 7 (24) 1, 2, 3, 7, 12, 13, 28
Type of software       
 Web-based 1 3 6 6 16 (55) 2, 3, 5, 7, 9, 12, 13, 14, 15, 16, 19, 20, 22, 23, 27, 28
 System inside the Electronic Health Record 3 1 2 6 12 (41) 4, 6, 8, 10, 11, 17, 21, 24, 25, 26, 18, 29
 Mobile 0 0 0 1 1 (3) 1
Type of institution promoting the study       
 Hospital 2 1 3 3 9 (31) 2, 4, 8, 17, 18, 21, 26, 27, 29
 University 1 1 3 4 9 (31) 5, 10, 11, 12, 13, 19, 20, 24, 25
 National institution 0 2 0 2 4 (14) 1, 9, 15, 22
 Regulatory authority 1 0 1 3 5 (17) 6, 7, 14, 16, 28
 Othera 0 0 1 1 2 (7) 3, 23
Target       
 Healthcare professionals 4 2 7 8 21 (72) 4, 6, 7, 8, 9, 10, 11, 13, 14, 16, 17, 18, 19, 21, 23, 24, 25, 26, 27, 28, 29.
 Patients 0 2 1 4 7 (24) 1, 2, 3, 5, 12, 20, 22
 Healthcare professionals and patients 0 0 0 1 1 (3) 15
Type of medicine       
 All 4 1 5 11 21 (72) 3, 4, 5, 6, 7, 8, 9, 11, 12, 14, 16, 17, 18, 19, 20, 21, 24, 25, 26, 28, 29
 Vaccines 0 2 1 2 5 (17) 1, 10, 13, 15, 22
 Chemotherapy 0 1 0 0 1 (3) 2
 Human albumin 0 0 1 0 1 (3) 23
 Radiopaque agents 0 0 1 0 1 (3) 27
Type of ADR       
 All 4 4 8 11 27 (93) 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
 Serious 0 0 0 2 2 (7) 1, 3
  1. a Other institutions are: Clinical trial team (project 23) and website producer (project 3)